Loading...
•
Mar 31, 2021
Bicycle Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021.
Key Takeaways
Bicycle Therapeutics reported its financial results for the first quarter ended March 31, 2021, highlighting the advancement of multiple Bicycle Toxin Conjugates® (BTCs) in the clinic and the preparation for BT7480 to enter the clinic later this year.
Advanced multiple Bicycle Toxin Conjugates® (BTCs) in the clinic.
Prepared for BT7480, a lead tumor-targeted immune cell agonist, to enter the clinic later this year.
Expanded the use of the Bicycle platform outside of oncology.
Significantly strengthened the balance sheet.
Forward Guidance
Bicycle Therapeutics plans to build on the momentum during the year, with a presentation of preclinical data at AACR highlighting the potential therapeutic benefits that Bicycles may offer for treating cancer and other serious diseases.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...